1. Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy.
- Author
-
Hayashi Y, Osawa K, Nakakaji R, Minamiyama S, Ohashi N, Ohya T, Iida M, Iwai T, Ozawa T, Oguri S, Koizumi T, Hirota M, Kioi M, Hata M, and Mitsudo K
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Cisplatin administration & dosage, Docetaxel administration & dosage, Female, Gingival Neoplasms mortality, Humans, Infusions, Intra-Arterial, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Treatment Outcome, Antineoplastic Agents administration & dosage, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell radiotherapy, Chemoradiotherapy, Gingival Neoplasms drug therapy, Gingival Neoplasms radiotherapy
- Abstract
Background: The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy., Methods: A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m
2 docetaxel and 150 mg/m2 cisplatin) and three-dimensional computed tomography based, daily conventional radiotherapy (total, 60 Gy/30 fr) for 6 weeks., Results: The median follow-up period was 40 months (range, 3-110 months). The 3-year overall survival and locoregional control rates for all patients were 64.3% and 84.3%, respectively. The OS rate of the patients with N0-1 was significantly higher than that of the patients with N ≥ 2 (P < .05). No grade 5 toxicities were observed., Conclusions: Intra-arterial infusion chemotherapy concurrent with radiotherapy was effective for advanced maxillary gingival SCC., (© 2019 Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF